ScholarLens Back to search
2023•Unpublished venueOpen access

Supplementary Methods from Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab In Vitro and in Xenograft Models

Sylvia Herter, Frank Herting, Olaf Mundigl, Inja Waldhauer, Tina Weinzierl, Tanja Fauti, Gunter Muth, Doris Ziegler-Landesberger, Erwin van Puijenbroek, Sabine Lang, Minh Ngoc Duong, Lina Reslan, Christian A. Gerdes, Thomas Friess, Ute Baer, Helmut J. BURTSCHER, Michael Weidner, Charles Dumontet, Pablo Umaña, Gerhard J. Niederfellner, Marina Bacac, Christian Georg Klein

Open full text 0 citations

Abstract

PDF file - 100K

Open-access reader

About this research paper

What this paper is about

PDF file - 100K

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

PDF file - 100K

Key concepts: Obinutuzumab, Ofatumumab, In vitro, Rituximab, CD20, Antibody, Medicine, Chemistry

Related papers

Related paper 1Related paper 2
Back to paper searchBrowse research topicsOriginal source
Supplementary Methods from Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab In Vitro and in Xenograft Models — Research Paper | ScholarLens